Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00372827

Enrollment

245

Registered

2006-09-07

Start date

2004-02-29

Completion date

2006-01-31

Last updated

2016-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Pigment Dispersion Glaucoma, Primary Open-angle Glaucoma

Brief summary

The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.

Interventions

DRUGBrinzolamide 1% added to Travoprost 0.004%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are treated with any prostaglandin analogue monotherapy (excluding unoprostone) and who have an intraocular pressure between 19 and 32 mmHg at 08:00 hours.

Exclusion criteria

* Under 18 years

Design outcomes

Primary

Measure	Time frame
Mean diurnal intraocular pressure at month 3	—

Secondary

Measure	Time frame
Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3.	—
Reduction from baseline in mean diurnal intraocular pressure and individual timepoints.	—
Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months.	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026